Hydroxyurea and hydroxamic acid derivatives as antitumor drugs (CROSBI ID 159185)
Prilog u časopisu | pregledni rad (stručni)
Podaci o odgovornosti
Šaban, Nina ; Bujak, Maro
engleski
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic acid derivatives that target specific enzymes involved in cancer progression such as histone deacetylasesm, matrix metalloproteinases and also RNR.
hydroxyurea. hydroxamic acid derivatives; cancer
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
64 (2)
2009.
213-221
objavljeno
0344-5704
10.1007/s00280-009-0991-z